| Hearthstone Health Campus | |
| 3043 North Lintel Drive, Bloomington, Indiana 47404 | |
| (812) 333-7622 | |
| Name | Hearthstone Health Campus |
|---|---|
| Location | 3043 North Lintel Drive, Bloomington, Indiana |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 64 |
| Occupancy Rate | 72.34% |
| Medicare ID (CCN) | 155818 |
| Legal Business Name | Daviess County Hospital |
| Ownership Type | Non Profit - Corporation |
| NPI Number | 1316375686 |
| Organization Name | DAVIESS COUNTY HOSPITAL |
| Doing Business As | HEARTHSTONE HEALTH CAMPUS |
| Address | 3043 N Lintel Dr, Bloomington, IN 47404 |
| Phone Number | 812-333-7622 |
News Archive
With employers and individuals continuing to struggle with rising health care costs, a new study shows there is one strategy that is proven to slow the pace of this ever increasing burden: preventive health. Published today in Population Health Management, "The Impact of The Prevention Plan on Employee Health Risk Reduction" reveals that prevention programs based on the clinical practice of preventive medicine are able to achieve measurable health risk reduction in just one year.
Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that seven abstracts related to two of the company's cardiac Positron Emission Tomography (PET) imaging candidates will be presented at ASNC2010, the 15th Annual Scientific Session of the American Society of Nuclear Cardiology, being held September 23-26, 2010 in Philadelphia.
Jobst Vascular Institute is conducting pioneering research that looks at using stents to treat blocked veins. For years, stents - small mesh tubes - have been used to treat narrowed or blocked arteries; however none are specifically designed for use in veins.
Transgene SA, a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and infectious diseases, today announced that favourable pre-clinical and clinical data on two Transgene products - TG1050 and TG4040 to treat chronic hepatitis B and chronic hepatitis C, respectively - will be presented in oral presentations at this year's European Association for the Study of the Liver Conference (Amsterdam, Netherlands, April 24-28, 2013).
HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue of $73.2 million for the fourth quarter ended December 31, 2014, a 38% increase compared to $53.1 million in revenue for the same period of 2013. For the fiscal year 2014, the company generated revenue of $278.4 million, a 34% increase compared to revenue of $207.9 million in 2013.
› Verified 3 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
With employers and individuals continuing to struggle with rising health care costs, a new study shows there is one strategy that is proven to slow the pace of this ever increasing burden: preventive health. Published today in Population Health Management, "The Impact of The Prevention Plan on Employee Health Risk Reduction" reveals that prevention programs based on the clinical practice of preventive medicine are able to achieve measurable health risk reduction in just one year.
Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that seven abstracts related to two of the company's cardiac Positron Emission Tomography (PET) imaging candidates will be presented at ASNC2010, the 15th Annual Scientific Session of the American Society of Nuclear Cardiology, being held September 23-26, 2010 in Philadelphia.
Jobst Vascular Institute is conducting pioneering research that looks at using stents to treat blocked veins. For years, stents - small mesh tubes - have been used to treat narrowed or blocked arteries; however none are specifically designed for use in veins.
Transgene SA, a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and infectious diseases, today announced that favourable pre-clinical and clinical data on two Transgene products - TG1050 and TG4040 to treat chronic hepatitis B and chronic hepatitis C, respectively - will be presented in oral presentations at this year's European Association for the Study of the Liver Conference (Amsterdam, Netherlands, April 24-28, 2013).
HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue of $73.2 million for the fourth quarter ended December 31, 2014, a 38% increase compared to $53.1 million in revenue for the same period of 2013. For the fiscal year 2014, the company generated revenue of $278.4 million, a 34% increase compared to revenue of $207.9 million in 2013.
› Verified 3 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $650 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 8.2 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 2.63 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 50.91 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 2.24 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 1.99 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 2.8 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 8.7 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 95.65 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 15.53 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 84.51 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 2.1 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 20.06 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 15.32 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 7.69 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 91.26 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 70.38 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 76.79 | 82.93 |
News Archive
With employers and individuals continuing to struggle with rising health care costs, a new study shows there is one strategy that is proven to slow the pace of this ever increasing burden: preventive health. Published today in Population Health Management, "The Impact of The Prevention Plan on Employee Health Risk Reduction" reveals that prevention programs based on the clinical practice of preventive medicine are able to achieve measurable health risk reduction in just one year.
Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that seven abstracts related to two of the company's cardiac Positron Emission Tomography (PET) imaging candidates will be presented at ASNC2010, the 15th Annual Scientific Session of the American Society of Nuclear Cardiology, being held September 23-26, 2010 in Philadelphia.
Jobst Vascular Institute is conducting pioneering research that looks at using stents to treat blocked veins. For years, stents - small mesh tubes - have been used to treat narrowed or blocked arteries; however none are specifically designed for use in veins.
Transgene SA, a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and infectious diseases, today announced that favourable pre-clinical and clinical data on two Transgene products - TG1050 and TG4040 to treat chronic hepatitis B and chronic hepatitis C, respectively - will be presented in oral presentations at this year's European Association for the Study of the Liver Conference (Amsterdam, Netherlands, April 24-28, 2013).
HeartWare International, Inc., a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenue of $73.2 million for the fourth quarter ended December 31, 2014, a 38% increase compared to $53.1 million in revenue for the same period of 2013. For the fiscal year 2014, the company generated revenue of $278.4 million, a 34% increase compared to revenue of $207.9 million in 2013.
› Verified 3 days ago
Garden Villa - Bloomington Location: 1100 S Curry Pk, Bloomington, Indiana 47403 Phone: (812) 339-1657 | |
Meadowood Health Pavilion Location: 2455 Tamarack Trail, Bloomington, Indiana 47408 Phone: (812) 336-7060 | |
Golden Living Center-bloomington Location: 155 E Burks Dr, Bloomington, Indiana 47401 Phone: (812) 332-4437 | |
Bloomington Nursing And Rehabilitation Center Location: 120 E Miller Dr, Bloomington, Indiana 47401 Phone: (812) 336-1055 | |
Bell Trace Health And Living Center Location: 725 Bell Trace Circle, Bloomington, Indiana 47408 Phone: (812) 323-2858 | |
Hearthstone Health Campus Location: 3043 North Lintel Drive, Bloomington, Indiana 47404 Phone: (812) 333-7622 |